The drug is a mixture of three monoclonal antibodies that target the Zaire ebolavirus strain, one of the four strains that can be fatal to humans. Patients are given the treatment once, and it is administered intravenously.
Inmazeb was tested in the Democratic Republic of Congo during an Ebola outbreak that killed nearly 2,300 people before it ended in June. The drug significantly improved study participants’ chances of survival when compared to a second experimental drug.
“Today’s action demonstrates the FDA’s ongoing commitment to responding to public health threats — both domestically and abroad — on the basis of science and data.” FDA Commissioner Stephen Hahn, MD, said in a news release. “This approval was made possible because of our steadfast dedication to facilitate the development of safe and effective treatments for infectious diseases as part of our vital public health mission.”
More articles on pharmacy:
6 key obstacles states face as they prepare for COVID-19 vaccine distribution
AstraZeneca loses lawsuit accusing it of monopolizing antipsychotic drug
Walgreens 4th-quarter sales at retail pharmacies up 3.6%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.